-
Sector Analysis
Gonorrhea: Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Gonorrhea Therapeutics. - In 2025, there were more than 2.75 million diagnosed incident cases of GC in the 16 countries covered in GlobalData’s epidemiology forecast. - The GC market remains largely generic, with approved treatments spanning several antibiotic classes including penicillin antibiotics, sulfonamides, fluoroquinolones, tetracyclines, azalide derivatives, aminopenicillins, and macrolides. - Treatment has evolved from fluoroquinolone monotherapy to ceftriaxone–azithromycin dual therapy and, since 2020, ceftriaxone 500...
-
Sector Analysis
Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035
Ulcerative colitis (UC) is the most common type of inflammatory bowel disease (IBD). Worldwide, the highest number of incident and prevalent cases of UC are reported in Europe and North America (Heydari et al., 2025). UC presents as a chronic disease in which abnormal reactions of the immune system cause inflammation and ulcers on the inner lining of the large intestine, especially the colon and rectum, causing complete damage to the lining (National Institute of Diabetes and Digestive and Kidney...
-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035. - In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035. - There will be an increase in therapies with longer duration of action, such...
-
Sector Analysis
Alzheimer’s Disease in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM.he US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2...
-
Sector Analysis
Parkinson's Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimated that the PD market was $3.3 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.2 billion, increasing at a compound annual growth rate (CAGR) of 7.9%. The major drivers of growth in the PD market will be the launch of several pipeline products including novel...
-
Sector Analysis
Acute-on-Chronic Liver Failure: Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Acute-on-Chronic Liver Failure Therapeutics. In 2025, there were 72,095 diagnosed incident cases of ACLF in the 16 countries covered in GlobalData’s epidemiology forecast. Acute-on-Chronic Liver Failure (ACLF) management is largely supportive and focused on complications because there is no approved therapy specifically for ACLF. Standard interventions include antimicrobials (e.g., piperacillin–tazobactam, ceftriaxone/cefotaxime, meropenem, vancomycin/linezolid), vasopressors and fluids (norepinephrine ± vasopressin), albumin/crystalloids, HBV antivirals (tenofovir or entecavir), and...
-
Sector Analysis
Emerging Market Outsourcing Report, Q3 2026
Why Does Pharmaceutical Outsourcing in Emerging Markets Matter? The pharmaceutical manufacturing landscape across emerging markets is evolving as companies respond to changing supply chain conditions, regulatory developments, clinical manufacturing requirements, and opportunities across contract manufacturing. This report provides a comprehensive view of the pharmaceutical outsourcing landscape in emerging markets for Q3 2026, covering trends affecting contract manufacturing organizations (CMOs), recent contract service agreements, M&A, financing, facility investments, inspection outcomes, and supply chain developments. The analysis covers critical components of the...
-
Sector Analysis
Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβ monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the...
-
Product Insights
Congestive Heart Failure (Heart Failure): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Congestive Heart Failure (Heart Failure) - Global Clinical Trials Review, 2026" provides an overview of Congestive Heart Failure (Heart Failure) Clinical trials scenario. This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2026" provides an overview of Gastroesophageal (GE) Junction Carcinomas Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.